KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 119 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,737,627 | -30.9% | 2,043,005 | -7.7% | 0.00% | – |
| Q2 2023 | $3,960,137 | -90.0% | 2,212,367 | -78.3% | 0.00% | -100.0% |
| Q1 2023 | $39,582,783 | -29.8% | 10,175,989 | -38.6% | 0.00% | 0.0% |
| Q4 2022 | $56,351,844 | +14.5% | 16,574,072 | +83.9% | 0.00% | -33.3% |
| Q3 2022 | $49,196,000 | +5.3% | 9,010,339 | -13.0% | 0.00% | 0.0% |
| Q2 2022 | $46,733,000 | -42.2% | 10,362,009 | -5.5% | 0.00% | -25.0% |
| Q1 2022 | $80,825,000 | +128.0% | 10,966,701 | +98.9% | 0.00% | +100.0% |
| Q4 2021 | $35,453,000 | -24.0% | 5,513,680 | -31.3% | 0.00% | 0.0% |
| Q3 2021 | $46,676,000 | -22.2% | 8,019,999 | +37.9% | 0.00% | -33.3% |
| Q2 2021 | $60,027,000 | +7.0% | 5,816,549 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $56,096,000 | -32.1% | 5,332,280 | -0.1% | 0.00% | -40.0% |
| Q4 2020 | $82,661,000 | +18.2% | 5,339,859 | +11.5% | 0.01% | 0.0% |
| Q3 2020 | $69,919,000 | -19.7% | 4,788,974 | +4.1% | 0.01% | -16.7% |
| Q2 2020 | $87,104,000 | +39.6% | 4,598,947 | +41.6% | 0.01% | +20.0% |
| Q1 2020 | $62,384,000 | +0.8% | 3,247,487 | +0.6% | 0.01% | +25.0% |
| Q4 2019 | $61,888,000 | +104.3% | 3,228,366 | +2.5% | 0.00% | +100.0% |
| Q3 2019 | $30,289,000 | +351.6% | 3,148,516 | +181.2% | 0.00% | +100.0% |
| Q2 2019 | $6,707,000 | +19.2% | 1,119,726 | +16.2% | 0.00% | – |
| Q1 2019 | $5,628,000 | -76.2% | 963,678 | -61.8% | 0.00% | -100.0% |
| Q4 2018 | $23,644,000 | -28.5% | 2,523,375 | +30.0% | 0.00% | -33.3% |
| Q3 2018 | $33,050,000 | -16.8% | 1,940,703 | -17.0% | 0.00% | 0.0% |
| Q2 2018 | $39,717,000 | +199.3% | 2,337,707 | +136.4% | 0.00% | +200.0% |
| Q1 2018 | $13,272,000 | +134.4% | 988,931 | +67.7% | 0.00% | – |
| Q4 2017 | $5,663,000 | -7.3% | 589,786 | +6.0% | 0.00% | -100.0% |
| Q3 2017 | $6,107,000 | +31.9% | 556,443 | +8.7% | 0.00% | – |
| Q2 2017 | $4,631,000 | -22.4% | 511,920 | +10.1% | 0.00% | -100.0% |
| Q1 2017 | $5,966,000 | +56.2% | 464,793 | +14.5% | 0.00% | – |
| Q4 2016 | $3,820,000 | +3.0% | 406,103 | +6.6% | 0.00% | – |
| Q3 2016 | $3,708,000 | +48.9% | 381,088 | +2.6% | 0.00% | – |
| Q2 2016 | $2,491,000 | -22.6% | 371,372 | +2.9% | 0.00% | – |
| Q1 2016 | $3,220,000 | -28.8% | 360,950 | +5.8% | 0.00% | – |
| Q4 2015 | $4,521,000 | +40.3% | 341,161 | +11.5% | 0.00% | – |
| Q3 2015 | $3,222,000 | -90.4% | 306,029 | -75.2% | 0.00% | -100.0% |
| Q2 2015 | $33,582,000 | +11.1% | 1,234,235 | +25.0% | 0.00% | +33.3% |
| Q1 2015 | $30,217,000 | +19.8% | 987,269 | +46.6% | 0.00% | 0.0% |
| Q4 2014 | $25,215,000 | +27.5% | 673,646 | +19.0% | 0.00% | +50.0% |
| Q3 2014 | $19,775,000 | +151.4% | 566,202 | +235.1% | 0.00% | +100.0% |
| Q2 2014 | $7,865,000 | +134.3% | 168,975 | +55.4% | 0.00% | – |
| Q1 2014 | $3,357,000 | +33.9% | 108,716 | -0.5% | 0.00% | – |
| Q4 2013 | $2,508,000 | – | 109,316 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |